Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis

Inflammatory Bowel Diseases

Volumn 19, Issue 2, 2013, Pages 246-253

  Perrier, Clémentine ^a,b   De Hertogh, Gert ^c   Cremer, Jonathan ^a   Vermeire, Severine ^a   Rutgeerts, Paul ^a   Van Assche, Gert ^a   Szymkowski, David E ^d   Ceuppens, Jan L ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d Xencor Inc   (United States)

Author keywords

Anti TNF treatment; Colitis; Inflammatory bowel disease; TNF; XENP1595

Indexed keywords

CNTO 5048; PHOSPHATE BUFFERED SALINE; RECOMBINANT TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; XENP 1595;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COLITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FLOW CYTOMETRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TISSUE SECTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; COLON; CYTOKINES; DRUG ADMINISTRATION SCHEDULE; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, SCID; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876419725     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.23023     Document Type: Article

References (36)

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361:2066-2078.
2. Peyrin-Biroulet L. Anti-TNF therapy in inflammatory bowel diseases: a huge review. Minerva Gastroenterol Dietol. 2010;56:233-243.
3. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
4. Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24:167-182.
5. Guerra I, Algaba A, Perez-Calle JL, et al. Induction of psoriasis with anti- TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis. 2012;6:518-523.
6. Horiuchi T, Mitoma H, Harashima S, et al. Transmembrane TNF- alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford). 2010;49:1215-1228.
7. Ruuls SR, Hoek RM, Ngo VN, et al. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity. 2001;15:533-543.
8. Zalevsky J, Secher T, Ezhevsky SA, et al. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol. 2007;179:1872-1883.
9. Taoufik E, Tseveleki V, Chu SY, et al. Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-kappaB. Brain. 2011; 134:2722-2735.
10. Alexopoulou L, Kranidioti K, Xanthoulea S, et al. Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity. Eur J Immunol. 2006;36: 2768-2780.
11. Torres D, Janot L, Quesniaux VF, et al. Membrane tumor necrosis factor confers partial protection to Listeria infection. Am J Pathol. 2005;167: 1677-1687.
12. Olleros ML, Guler R, Vesin D, et al. Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infections. Am J Pathol. 2005;166:1109-1120.
13. Fremond C, Allie N, Dambuza I, et al. Membrane TNF confers protection to acute mycobacterial infection. Respir Res. 2005;6:136.
14. Jacobs M, Samarina A, Grivennikov S, et al. Reactivation of tuberculosis by tumor necrosis factor neutralization. Eur Cytokine Netw. 2007; 18:5-13.
15. Silva LC, Ortigosa LC, Benard G. Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy. 2010;2:817-833.
16. Vos AC, Wildenberg ME, Duijvestein M, et al. Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc regiondependent manner. Gastroenterology. 2011;140:221-230.
17. Di Sabatino A, Ciccocioppo R, Cinque B, et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut. 2004;53:70-77.
18. ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002;50:206-211.
19. Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 2001;121:1145-1157.
20. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088-1094.
21. Bourne T, Fossati G, Nesbitt A. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. BioDrugs. 2008;22:331-337.
22. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005;129:807-818.
23. Powrie F, Leach MW, Mauze S, et al. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity. 1994;1:553-562.
24. Liu Z, Jiu J, Liu S, et al. Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin- 23 secretion. J Autoimmun. 2007;29:187-194.
25. Steed PM, Tansey MG, Zalevsky J, et al. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science. 2003;301: 1895-1898.
26. Vincent M, Sayre NL, Graham MJ, et al. Evaluation of an anti-tumor necrosis factor therapeutic in a mouse model of Niemann-Pick C liver disease. PLoS One. 2010;5:e12941.
27. Chaudhry A, Rudra D, Treuting P, et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science. 2009; 326:986-991.
28. Corazza N, Brunner T, Buri C, et al. Transmembrane tumor necrosis factor is a potent inducer of colitis even in the absence of its secreted form. Gastroenterology. 2004;127:816-825.
29. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244-279.
30. Dayer Schneider J, Seibold I, Saxer-Sekulic N, et al. Lack of TNFR2 expression by CD4(+) T cells exacerbates experimental colitis. Eur J Immunol. 2009;39:1743-1753.
31. Muller S, Rihs S, Schneider JM, et al. Soluble TNF-alpha but not transmembrane TNF-alpha sensitizes T cells for enhanced activation- induced cell death. Eur J Immunol. 2009;39:3171-3180.
32. Suvannavejh GC, Lee HO, Padilla J, et al. Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis. Cell Immunol. 2000;205:24-33.
33. Brambilla R, Ashbaugh JJ, Magliozzi R, et al. Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain. 2011;134:2736-2754.
34. Khera TK, Copland DA, Boldison J, et al. Tumour necrosis factormediated macrophage activation in the target organ is critical for clinical manifestation of uveitis. Clin Exp Immunol. 2012;168:165-177.
35. Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009;131:308-316.
36. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore). 2008;87:345-364.